Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification
In Vivo · 2026
DOI: 10.21873/invivo.14464 ↗Kurz gefasst
Fallbericht in der Zeitschrift In Vivo, 2026. Verfasst von Hirotaka Suto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan; hirotaka.suto@hyogo-cc.jp. Hauptthemen laut MEDLINE: Tegafur, Oxonic Acid, Salivary Gland Neoplasms, Salivary Ducts. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan; hirotaka.suto@hyogo-cc.jp.
- Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
- Department of Diagnostic Pathology, Hyogo Cancer Center, Akashi, Japan.
Zitieren
APA
Suto, H., Kawamura, M., Morita, M., Sakai, H., Onoe, T., Ikeuchi, K., Maeda, N., & Matsumoto, K. (2026). Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification. In Vivo. https://doi.org/10.21873/invivo.14464
Vancouver
Suto H, Kawamura M, Morita M, Sakai H, Onoe T, Ikeuchi K, et al. Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification. In Vivo. 2026. doi:10.21873/invivo.14464
BibTeX
@article{Suto2026,
author = {Suto, Hirotaka and Kawamura, Miyuki and Morita, Mitsunori and Sakai, Hideki and Onoe, Takuma and Ikeuchi, Kyoko and Maeda, Naoko and Matsumoto, Koji},
title = {Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14464}
}
EUVIMED